Please assess the completion status of the following clinical trial:

Trial Title: Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of multiple myeloma~  * Newly diagnosed disease~ * Symptomatic disease~* Measurable or evaluable disease, defined by ≥ 1 of the following criteria:~  * Serum monoclonal protein ≥ 1.0 g by protein electrophoresis~ * Monoclonal protein \> 200 mg by 24-hour urine electrophoresis~ * Serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio~ * Monoclonal bone marrow plasmacytosis ≥ 30% (evaluable disease)~ * Measurable soft tissue plasmacytoma not previously irradiated~* No monoclonal gammopathy of undetermined significance or smoldering myeloma~PATIENT CHARACTERISTICS:~* ECOG performance status (PS) 0-2 (ECOG PS 3 allowed if secondary to pain)~* ANC ≥ 1,500/mm\^3~* Platelet count ≥ 75,000/mm\^3~* Hemoglobin ≥ 8.0 g/dL~* Creatinine ≤ 2.5 mg/dL~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective double-method contraception (1 highly effective and 1 additional method) for 1 month before, during, and for 4 weeks after completion of study therapy~* No uncontrolled infection~* No other active malignancy~* No other malignancies within the past 5 years except for currently treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast~* No NYHA class III-IV congestive heart failure~* No untreated active deep vein thrombosis~PRIOR CONCURRENT THERAPY:~* At least 3 weeks since prior radiotherapy for solitary plasmacytoma~* Prior clarithromycin, therapeutic dehydroepiandrosterone (DHEA), anakinra, pamidronate disodium, or zoledronic acid allowed~* No prior cytotoxic chemotherapy~* No prior corticosteroids (except for treatment of a nonmalignant disorder)~* Concurrent corticosteroids (prednisone ≤ 20 mg/per day) allowed~* No concurrent radiotherapy except palliative radiotherapy for a single painful bone lesion or fracture

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide/Cyclophosphamide/Dexamethasone (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).